The Food and Drug Administration affirmed its negative clinical review of Sarepta Therapeutics Inc.'s (Nasdaq: SRPT) Duchenne muscular dystrophy treatment eteplirsen sending the stock price plummeting $8.88 to $10.82.
FDA affirms negative review of Sarepta's eteplirsen
April 21, 2016 at 14:05 PM EDT
